

# Stephen J Russell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2777610/stephen-j-russell-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

321 papers	14,731 citations	64 h-index	113 g-index
327 ext. papers	16,528 ext. citations	6.1 avg, IF	6.56 L-index

#	Paper	IF	Citations
321	Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.. <i>Vaccine</i> , <b>2022</b> ,	4.1	3
320	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , <b>2021</b> , 105, 1615-1624	1.8	
319	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFN $\beta$ IS). <i>Blood</i> , <b>2021</b> , 138, 1333-1333	2.2	
318	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , <b>2021</b> , 138, 2700-2700	2.2	
317	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , <b>2021</b> , 138, 119-119	2.2	
316	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 2650-2650	2.2	
315	Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 29, 100473	2	0
314	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , <b>2021</b> ,	10.7	5
313	Oncolytic Foamy Virus - generation and properties of a nonpathogenic replicating retroviral vector system that targets chronically proliferating cancer cells. <i>Journal of Virology</i> , <b>2021</b> ,	6.6	3
312	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 677-687	6.4	4
311	Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100225	18	5
310	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 1546-1577	6.4	8
309	A brief review of reporter gene imaging in oncolytic virotherapy and gene therapy. <i>Molecular Therapy - Oncolytics</i> , <b>2021</b> , 21, 98-109	6.4	4
308	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 451-460.e2	2	2
307	Improved Noninvasive InVivo Tracking of AAV-9 Gene Therapy Using the Perchlorate-Resistant Sodium Iodide Symporter from Minke Whale. <i>Molecular Therapy</i> , <b>2021</b> , 29, 236-243	11.7	1
306	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 354-361	3.8	3
305	MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009283	7.6	5

304	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 1035-1046	12.5	2
303	The long-lasting enigma of polycytidine (polyC) tract. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009739	7.6	1
302	MicroRNA-detargeting proves more effective than gene deletion for improving safety of oncolytic Mengovirus in a nude mouse model. <i>Molecular Therapy - Oncolytics</i> , <b>2021</b> , 23, 1-13	6.4	0
301	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 446-454	7.1	3
300	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1297-1304	4.4	3
299	Mapping of Ion and Substrate Binding Sites in Human Sodium Iodide Symporter (hNIS). <i>Journal of Chemical Information and Modeling</i> , <b>2020</b> , 60, 1652-1665	6.1	5
298	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 637-642	7.1	6
297	Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 17, 484-495	6.4	8
296	Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS). <i>PLoS ONE</i> , <b>2020</b> , 15, e0229085	3.7	7
295	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 4	7	12
294	Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. <i>Leukemia</i> , <b>2020</b> , 34, 3310-3322	10.7	29
293	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	1
292	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	2
291	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	1
290	Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 18, 546-555	6.4	2
289	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 53-56	2	5
288	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 310-315	7.1	16
287	Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 16, 63-74	6.4	14

286	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E60-E62	7.1	1
285	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , <b>2020</b> , 34, 1135-1143	10.7	19
284	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1280-1287	7.1	10
283	Collateral Lethal Effects of Complementary Oncolytic Viruses. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 18, 236-246	6.4	1
282	Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2057-2067	6.1	9
281	Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging. <i>Cancer Gene Therapy</i> , <b>2020</b> , 27, 179-188	5.4	12
280	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2020</b> , 27, 13-16	2.7	21
279	Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) <b>2020</b> , 15, e0229085		
278	Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) <b>2020</b> , 15, e0229085		
277	Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) <b>2020</b> , 15, e0229085		
276	Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS) <b>2020</b> , 15, e0229085		
275	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 811-814	10.7	15
274	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 1834-1839	6.4	4
273	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 32	7	22
272	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 751-756	7.1	6
271	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 254-260	4.5	8
270	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 1268-1272	10.7	4
269	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 353-367	4.4	51

268	Oncolytic Viruses: Priming Time for Cancer Immunotherapy. <i>BioDrugs</i> , <b>2019</b> , 33, 485-501	7.9	52
267	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 588-594	4.5	26
266	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2019</b> , 26, 101-102	2.7	4
265	Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins. <i>Viruses</i> , <b>2019</b> , 11,	6.2	9
264	Monoclonal gammopathy-associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E250-E253	7.1	17
263	Dual-Isotope SPECT Imaging with NIS Reporter Gene and Duramycin to Visualize Tumor Susceptibility to Oncolytic Virus Infection. <i>Molecular Therapy - Oncolytics</i> , <b>2019</b> , 15, 178-185	6.4	4
262	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , <b>2019</b> , 134, 4334-4334	2.2	1
261	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1905-1905	2.2	1
260	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , <b>2019</b> , 134, 5523-5523	2.2	
259	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 5833-5833	2.2	
258	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1904-1904	2.2	
257	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 2197-2197	2.2	
256	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , <b>2019</b> , 134, 5490-5490	2.2	1
255	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , <b>2019</b> , 33, 1273-1277	10.7	7
254	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 472-483	6.4	33
253	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 1930-1938	7.8	20
252	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , <b>2019</b> , 33, 527-531	10.7	30
251	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 306-311	7.1	9

250	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , <b>2018</b> , 32, 1421-1426	10.7	5
249	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , <b>2018</b> , 32, 2240-2249	10.7	49
248	Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. <i>Cancer Cell</i> , <b>2018</b> , 33, 599-605	24.3	101
247	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , <b>2018</b> , 32, 1811-1815	10.7	18
246	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 326-333	4.4	4
245	Synthesis and evaluation of F-hexafluorophosphate as a novel PET probe for imaging of sodium/iodide symporter in a murine C6-glioma tumor model. <i>Bioorganic and Medicinal Chemistry</i> , <b>2018</b> , 26, 225-231	3.4	16
244	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 179-186	7.1	29
243	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , <b>2018</b> , 93, 17-22	7.1	9
242	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1207-1210	7.1	1
241	Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV Cancers. <i>Molecular Therapy - Oncolytics</i> , <b>2018</b> , 10, 1-13	6.4	6
240	For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough). <i>Molecular Therapy</i> , <b>2018</b> , 26, 1876-1880	11.7	2
239	Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. <i>Current Cancer Drug Targets</i> , <b>2018</b> , 18, 177-187	2.8	73
238	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 59	7	115
237	Hemagglutinin-specific neutralization of subacute sclerosing panencephalitis viruses. <i>PLoS ONE</i> , <b>2018</b> , 13, e0192245	3.7	8
236	GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. <i>Blood</i> , <b>2018</b> , 132, 961-961	2.2	3
235	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , <b>2018</b> , 132, 3228-3228	2.2	
234	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3159-3159		
233	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3158-3158	2.2	

232	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4449-4449	2.2	
231	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , <b>2018</b> , 132, 3226-3226		
230	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4497-4497	2.2	
229	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , <b>2018</b> , 132, 4502-4502	2.2	
228	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , <b>2018</b> , 132, 5594-5594	2.2	
227	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , <b>2018</b> , 132, 3227-3227	2.2	
226	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , <b>2018</b> , 132, 3268-3268	2.2	
225	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4615-4615	2.2	
224	Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 316-326	6.1	34
223	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 116	7	38
222	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 125	7	17
221	New transgenic NIS reporter rats for longitudinal tracking of fibrogenesis by high-resolution imaging. <i>Scientific Reports</i> , <b>2018</b> , 8, 14209	4.9	2
220	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 435-440	7.1	10
219	Designing and building oncolytic viruses. <i>Future Virology</i> , <b>2017</b> , 12, 193-213	2.4	79
218	Oncolytic Virotherapy: A Contest between Apples and Oranges. <i>Molecular Therapy</i> , <b>2017</b> , 25, 1107-1116	11.7	76
217	Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2017</b> , 313, H392-H407	5.2	25
216	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E507-E512	7.1	3
215	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 668-673	7.1	46

214	Antigenic Drift Defines a New D4 Subgenotype of Measles Virus. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	17
213	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 578-598	6.4	88
212	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 549-554	7.1	18
211	Safety, pharmacokinetics, metabolism and radiation dosimetry of F-tetrafluoroborate (F-TFB) in healthy human subjects. <i>EJNMMI Research</i> , <b>2017</b> , 7, 90	3.6	14
210	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 908-917	6.4	43
209	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 888-895	4.5	14
208	MicroRNA-based Regulation of Picornavirus Tropism. <i>Journal of Visualized Experiments</i> , <b>2017</b> ,	1.6	4
207	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1146-1155	7.1	22
206	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2017</b> , 24, 183-188	2.7	1
205	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , <b>2017</b> , 130, 1198-1204	2.2	46
204	Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 170-172	4.5	7
203	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 50-55	7.1	30
202	How to develop viruses into anticancer weapons. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006190	7.6	17
201	Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma. <i>Oncotarget</i> , <b>2017</b> , 8, 63096-63109	3.3	5
200	Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN $\beta$ IS. <i>Human Gene Therapy Clinical Development</i> , <b>2016</b> , 27, 111-22	3.2	30
199	Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. <i>Blood</i> , <b>2016</b> , 127, 1449-58	2.2	81
198	Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 349ra99	17.5	41
197	Synthesis of <sup>18</sup> F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1454-9	8.9	22

196	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 473-5	7.1	20
195	Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses. <i>Molecular Therapy</i> , <b>2016</b> , 24, 306-317	11.7	23
194	MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy. <i>Journal of Virology</i> , <b>2016</b> , 90, 4078-4092	6.6	26
193	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 1284-9	4.3	21
192	The use of the NIS reporter gene for optimizing oncolytic virotherapy. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 15-32	5.4	44
191	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 2082-2082	2.2	1
190	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , <b>2016</b> , 128, 3272-3272	2.2	1
189	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 3317-3317	2.2	3
188	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 3444-3444	2.2	1
187	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , <b>2016</b> , 128, 4627-4627	2.2	1
186	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 5615-5615	2.2	
185	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , <b>2016</b> , 128, 3273-3273	2.2	
184	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , <b>2016</b> , 128, 3251-3251	2.2	
183	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 5480-5480	2.2	1
182	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , <b>2016</b> , 128, 3306-3306	2.2	
181	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 1194-1194	2.2	
180	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , <b>2016</b> , 128, 3269-3269	2.2	
179	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 3338-3338	2.2	

178	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , <b>2016</b> , 128, 3255-3255	2.2	
177	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 2187-2187	2.2	
176	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. <i>Cancer</i> , <b>2016</b> , 122, 2197-205	6.4	28
175	A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable and Functional Smooth Muscle Cells. <i>Stem Cells</i> , <b>2016</b> , 34, 1354-68	5.8	1
174	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 984-8	7.1	37
173	Recombinant mumps virus as a cancer therapeutic agent. <i>Molecular Therapy - Oncolytics</i> , <b>2016</b> , 3, 16019	6.4	12
172	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , <b>2016</b> , 101, 1102-9	6.6	9
171	Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model. <i>Molecular Therapy</i> , <b>2016</b> , 24, 2109-2117	11.7	12
170	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , <b>2016</b> , 91, 1354-1361	6.4	30
169	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1123-1128	7.1	52
168	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 585-9	7.1	40
167	Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 1054-81	6.4	81
166	Erratum for Tesfay et al., PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice. <i>Journal of Virology</i> , <b>2015</b> , 89, 2453-2453	6.6	78
165	Cardiac AAV9 Gene Delivery Strategies in Adult Canines: Assessment by Long-term Serial SPECT Imaging of Sodium Iodide Symporter Expression. <i>Molecular Therapy</i> , <b>2015</b> , 23, 1211-1221	11.7	12
164	Correction for Tesfay et al., Vesiculovirus Neutralization by Natural IgM and Complement. <i>Journal of Virology</i> , <b>2015</b> , 89, 1945-1946	6.6	78
163	MicroRNAs and oncolytic viruses. <i>Current Opinion in Virology</i> , <b>2015</b> , 13, 40-8	7.5	49
162	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 524-8	7.1	25
161	Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 22-30	10.1	120

160	Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity. <i>Molecular Therapy - Oncolytics</i> , <b>2015</b> , 2, 15012	6.4	7
159	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 981-5	7.1	28
158	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , <b>2015</b> , 126, 3177-3177	2.2	3
157	Thrombotic Microangiopathy in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 5317-5317	2.2	2
156	Vesicular stomatitis virus expressing interferon- $\beta$ s oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 33165-77	3.3	69
155	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4176-4176	2.2	
154	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , <b>2015</b> , 126, 5303-5303	2.2	
153	Vesiculovirus neutralization by natural IgM and complement. <i>Journal of Virology</i> , <b>2014</b> , 88, 6148-57	6.6	26
152	Oncolytic vaccinia virotherapy for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 722-9	4.9	12
151	Intravascular cell delivery device for therapeutic VEGF-induced angiogenesis in chronic vascular occlusion. <i>Biomaterials</i> , <b>2014</b> , 35, 9012-22	15.6	7
150	Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus. <i>Journal of Virology</i> , <b>2014</b> , 88, 8332-9	6.6	23
149	Antibody neutralization of retargeted measles viruses. <i>Virology</i> , <b>2014</b> , 454-455, 237-46	3.6	14
148	Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 194-202	4.9	17
147	Remission of disseminated cancer after systemic oncolytic virotherapy. <i>Mayo Clinic Proceedings</i> , <b>2014</b> , 89, 926-33	6.4	202
146	Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. <i>Molecular Therapy - Oncolytics</i> , <b>2014</b> , 1, 14005	6.4	20
145	Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors. <i>Virus Adaptation and Treatment</i> , <b>2014</b> , 11		
144	Biological Therapy for Multiple Myeloma <b>2014</b> , 141-158		
143	Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. <i>Journal of Translational Medicine</i> , <b>2013</b> , 11, 20	8.5	97

142	Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 999-1006	13.4	64
141	Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. <i>Journal of Virology</i> , <b>2013</b> , 87, 13543-55	6.6	26
140	Enhancing cytokine-induced killer cell therapy of multiple myeloma. <i>Experimental Hematology</i> , <b>2013</b> , 41, 508-17	3.1	20
139	Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. <i>Experimental Hematology</i> , <b>2013</b> , 41, 1038-49	3.1	21
138	Oncolytic vaccines. <i>Expert Review of Vaccines</i> , <b>2013</b> , 12, 1155-72	5.2	35
137	Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. <i>Molecular Therapy</i> , <b>2013</b> , 21, 1930-7	11.7	12
136	Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. <i>Human Gene Therapy Clinical Development</i> , <b>2013</b> , 24, 174-81	3.2	34
135	PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. <i>Journal of Virology</i> , <b>2013</b> , 87, 3752-9	6.6	51
134	Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. <i>Scientific Reports</i> , <b>2013</b> , 3, 2375	4.9	38
133	Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. <i>PLoS ONE</i> , <b>2013</b> , 8, e73759	3.7	23
132	Survival Outcomes Of Very Young (. <i>Blood</i> , <b>2013</b> , 122, 2136-2136	2.2	1
131	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , <b>2013</b> , 122, 3095-3095	2.2	1
130	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , <b>2013</b> , 122, 3117-3117	2.2	2
129	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , <b>2013</b> , 122, 3119-3119	2.2	3
128	Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. <i>PLoS ONE</i> , <b>2013</b> , 8, e52306	3.7	20
127	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1979-1979	2.2	
126	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 3209-3209	2.2	
125	Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. <i>Human Gene Therapy</i> , <b>2012</b> , 23, 484-91	4.8	37

124	Oncolytic virotherapy. <i>Nature Biotechnology</i> , <b>2012</b> , 30, 658-70	44.5	947
123	Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. <i>Journal of Gene Medicine</i> , <b>2012</b> , 14, 590-7	3.5	11
122	Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. <i>BMC Cancer</i> , <b>2012</b> , 12, 508	4.8	26
121	Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. <i>Human Gene Therapy</i> , <b>2012</b> , 23, 295-301	4.8	36
120	The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. <i>Current Gene Therapy</i> , <b>2012</b> , 12, 33-47	4.3	105
119	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. <i>Blood</i> , <b>2012</b> , 120, 1858-1858	2.2	1
118	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , <b>2012</b> , 120, 201-201	2.2	15
117	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , <b>2012</b> , 120, 3972-3972	2.2	6
116	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , <b>2012</b> , 120, 946-946	2.2	1
115	Oncolytic measles virus retargeting by ligand display. <i>Methods in Molecular Biology</i> , <b>2012</b> , 797, 141-62	1.4	15
114	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , <b>2012</b> , 120, 2973-2973	2.2	
113	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , <b>2012</b> , 120, 448-448	2.2	
112	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 1988-1988	2.2	
111	Multiple myeloma and the road to personalised medicine. <i>Lancet Oncology</i> , <b>2011</b> , 12, 617-9	21.7	44
110	Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. <i>Molecular Therapy</i> , <b>2011</b> , 19, 1041-7	11.7	15
109	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , <b>2011</b> , 118, 2887-2887	2.2	1
108	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , <b>2011</b> , 118, 2942-2942	2.2	2
107	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. <i>Blood</i> , <b>2011</b> , 118, 3963-3963	2.2	4

106	Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. <i>Journal of Virology</i> , <b>2010</b> , 84, 1550-62	6.6	88
105	Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. <i>Human Gene Therapy</i> , <b>2010</b> , 21, 451-62	4.8	56
104	Infection and killing of multiple myeloma by adenoviruses. <i>Human Gene Therapy</i> , <b>2010</b> , 21, 179-90	4.8	38
103	Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. <i>Human Gene Therapy</i> , <b>2010</b> , 21, 51-64	4.8	54
102	Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 875-82	10.1	210
101	MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. <i>PLoS Pathogens</i> , <b>2010</b> , 6, e1000820	7.6	45
100	Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. <i>American Journal of Roentgenology</i> , <b>2010</b> , 195, 341-9	5.4	59
99	Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. <i>Molecular Therapy</i> , <b>2010</b> , 18, 1155-64	11.7	58
98	Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. <i>Neoplasia</i> , <b>2010</b> , 12, 980-92	6.4	26
97	Use of attenuated paramyxoviruses for cancer therapy. <i>Expert Review of Vaccines</i> , <b>2010</b> , 9, 1275-302	5.2	44
96	Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 122, 745-54	4.4	54
95	Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. <i>Expert Opinion on Biological Therapy</i> , <b>2009</b> , 9, 1163-76	5.4	84
94	Converting tumor-specific markers into reporters of oncolytic virus infection. <i>Molecular Therapy</i> , <b>2009</b> , 17, 1395-403	11.7	16
93	Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. <i>Molecular Therapy</i> , <b>2009</b> , 17, 2041-8	11.7	70
92	Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. <i>Molecular Therapy</i> , <b>2009</b> , 17, 1012-21	11.7	32
91	Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. <i>American Journal of Roentgenology</i> , <b>2009</b> , 192, 279-87	5.4	66
90	MicroRNAs and the regulation of vector tropism. <i>Molecular Therapy</i> , <b>2009</b> , 17, 409-16	11.7	84
89	Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. <i>Journal of General Virology</i> , <b>2009</b> , 90, 693-701	4.9	19

88	Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 401-7	7.1	46
87	Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. <i>Journal of Gene Medicine</i> , <b>2009</b> , 11, 197-206	3.5	10
86	Engineered measles virus as a novel oncolytic therapy against prostate cancer. <i>Prostate</i> , <b>2009</b> , 69, 82-91	4.2	76
85	Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. <i>Prostate</i> , <b>2009</b> , 69, 1128-41	4.2	44
84	Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7246-55	12.9	150
83	Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. <i>Cancer Research</i> , <b>2009</b> , 69, 1459-68	10.1	58
82	Measles virus for cancer therapy. <i>Current Topics in Microbiology and Immunology</i> , <b>2009</b> , 330, 213-41	3.3	118
81	Engineering microRNA responsiveness to decrease virus pathogenicity. <i>Nature Medicine</i> , <b>2008</b> , 14, 1278-83	3.5	179
80	Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. <i>Molecular Therapy</i> , <b>2008</b> , 16, 1556-64	11.7	62
79	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , <b>2008</b> , 111, 2516-20	2.2	1753
78	Modeling of cancer virotherapy with recombinant measles viruses. <i>Journal of Theoretical Biology</i> , <b>2008</b> , 252, 109-22	2.3	103
77	Exploiting the high-affinity phosphonate/hydroxyapatite nanoparticle interaction for delivery of radiation and drugs. <i>Journal of Nanoparticle Research</i> , <b>2008</b> , 10, 141-150	2.3	58
76	Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy <b>2008</b> , 431-445		1
75	The utility of cells as vehicles for oncolytic virus therapies. <i>Current Opinion in Molecular Therapeutics</i> , <b>2008</b> , 10, 380-6		23
74	Engineering targeted viral vectors for gene therapy. <i>Nature Reviews Genetics</i> , <b>2007</b> , 8, 573-87	30.1	534
73	Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. <i>Molecular Therapy</i> , <b>2007</b> , 15, 114-22	11.7	105
72	Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. <i>Molecular Therapy</i> , <b>2007</b> , 15, 677-86	11.7	76
71	Engineering oncolytic measles virus to circumvent the intracellular innate immune response. <i>Molecular Therapy</i> , <b>2007</b> , 15, 588-97	11.7	73

70	Affinity thresholds for membrane fusion triggering by viral glycoproteins. <i>Journal of Virology</i> , <b>2007</b> , 81, 13149-57	6.6	54
69	Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. <i>Blood</i> , <b>2007</b> , 110, 2342-50	2.2	107
68	Viruses as anticancer drugs. <i>Trends in Pharmacological Sciences</i> , <b>2007</b> , 28, 326-33	13.2	144
67	History of oncolytic viruses: genesis to genetic engineering. <i>Molecular Therapy</i> , <b>2007</b> , 15, 651-9	11.7	441
66	Tumor Associated Macrophages (TAM) in Skeletal Plasmacytomas of Patients with Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 114-114	2.2	1
65	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , <b>2007</b> , 110, 2477-2477	2.2	1
64	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 1181-1181	2.2	
63	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. <i>Blood</i> , <b>2007</b> , 110, 3608-3608	2.2	
62	Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. <i>Experimental Hematology</i> , <b>2006</b> , 34, 713-20	3.1	90
61	Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. <i>Hepatology</i> , <b>2006</b> , 44, 1465-77	11.2	95
60	Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1868-75	12.9	92
59	In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. <i>Molecular Imaging and Biology</i> , <b>2006</b> , 8, 324-32	3.8	48
58	Enhancing the therapeutic index of radiation in multiple myeloma. <i>Drug Discovery Today Disease Mechanisms</i> , <b>2006</b> , 3, 515-522		5
57	Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. <i>Cancer Research</i> , <b>2006</b> , 66, 11840-50	10.1	88
56	Mathematical modeling of cancer radiovirotherapy. <i>Mathematical Biosciences</i> , <b>2006</b> , 199, 55-78	3.9	87
55	Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative <sup>153</sup> Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. <i>Blood</i> , <b>2006</b> , 107, 4063-70	2.2	33
54	Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. <i>Molecular Imaging and Biology</i> , <b>2006</b> , 8, 16-23	3.8	52
53	A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 99, 177-84	4.4	72

52	In-111DAC Is a Novel Technique To Image Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 3488-3488	2.2	1
51	Fully Retargeted Oncolytic Measles Virus for Multiple Myeloma Therapy.. <i>Blood</i> , <b>2006</b> , 108, 5474-5474	2.2	
50	Rescue and propagation of fully retargeted oncolytic measles viruses. <i>Nature Biotechnology</i> , <b>2005</b> , 23, 209-14	44.5	208
49	Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. <i>Cancer Gene Therapy</i> , <b>2005</b> , 12, 593-9	5.4	49
48	PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. <i>Experimental Hematology</i> , <b>2005</b> , 33, 784-95	3.1	48
47	Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. <i>Cancer Research</i> , <b>2005</b> , 65, 5292-300	10.1	57
46	A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. <i>Molecular Therapy</i> , <b>2005</b> , 12, 835-41	11.7	51
45	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 781-781	2.2	3
44	High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. <i>Cancer Research</i> , <b>2004</b> , 64, 4919-26	10.1	237
43	Reengineering paramyxovirus tropism. <i>Virology</i> , <b>2004</b> , 329, 217-25	3.6	41
42	Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. <i>Journal of Gene Medicine</i> , <b>2004</b> , 6, 1082-91	3.5	32
41	Oncolytic measles viruses for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , <b>2004</b> , 4, 1685-92	5.4	47
40	Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 325, 157-66	3.4	34
39	Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. <i>Blood</i> , <b>2004</b> , 103, 1641-6	2.2	272
38	Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , <b>2004</b> , 104, 331-331	2.2	11
37	Genetic Targeting of Retroviral Vectors <b>2003</b> , 267-291		1
36	Genetically targeted radiotherapy for multiple myeloma. <i>Blood</i> , <b>2003</b> , 102, 489-96	2.2	80
35	Avian leukosis virus is a versatile eukaryotic platform for polypeptide display. <i>Virology</i> , <b>2003</b> , 315, 303-13	3.6	12

34	Epitope selection from an uncensored peptide library displayed on avian leukosis virus. <i>Virology</i> , <b>2003</b> , 315, 313-21	3.6	19
33	In vivo imaging and tumor therapy with the sodium iodide symporter. <i>Journal of Cellular Biochemistry</i> , <b>2003</b> , 90, 1079-86	4.7	72
32	Primer on medical genomics. Part X: Gene therapy. <i>Mayo Clinic Proceedings</i> , <b>2003</b> , 78, 1370-83	6.4	11
31	Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. <i>Cancer Research</i> , <b>2003</b> , 63, 2462-9	10.1	187
30	RNA viruses as virotherapy agents. <i>Cancer Gene Therapy</i> , <b>2002</b> , 9, 961-6	5.4	130
29	Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. <i>Nature Medicine</i> , <b>2002</b> , 8, 527-31	50.5	148
28	Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. <i>Blood</i> , <b>2002</b> , 99, 2342-50	2.2	85
27	Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2210-6	12.9	187
26	Intraperitoneal therapy of ovarian cancer using an engineered measles virus. <i>Cancer Research</i> , <b>2002</b> , 62, 4656-62	10.1	168
25	Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. <i>Blood</i> , <b>2001</b> , 97, 3746-54	2.2	200
24	Systemic therapy of myeloma xenografts by an attenuated measles virus. <i>Blood</i> , <b>2001</b> , 98, 2002-7	2.2	153
23	Retargeting gene delivery using surface-engineered retroviral vector particles. <i>Current Opinion in Biotechnology</i> , <b>2001</b> , 12, 461-6	11.4	72
22	Concentration of viral vectors by co-precipitation with calcium phosphate. <i>Journal of Gene Medicine</i> , <b>2001</b> , 3, 188-94	3.5	46
21	Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. <i>Journal of Virology</i> , <b>2001</b> , 75, 2087-96	6.6	107
20	Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein. <i>Journal of Virology</i> , <b>2001</b> , 75, 3685-95	6.6	68
19	Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. <i>Human Gene Therapy</i> , <b>2001</b> , 12, 811-21	4.8	86
18	Gene therapy approaches for multiple myeloma. <i>Seminars in Hematology</i> , <b>2001</b> , 38, 268-75	4	9
17	Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. <i>Cancer Gene Therapy</i> , <b>2000</b> , 7, 526-9	5.4	10

16	A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. <i>Human Gene Therapy</i> , <b>2000</b> , 11, 817-26	4.8	49
15	Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. <i>Journal of Virology</i> , <b>2000</b> , 74, 295-304	6.6	74
14	Recombinant measles viruses efficiently entering cells through targeted receptors. <i>Journal of Virology</i> , <b>2000</b> , 74, 9928-36	6.6	97
13	Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. <i>Human Gene Therapy</i> , <b>1999</b> , 10, 1533-44	4.8	54
12	Viral vector targeting. <i>Current Opinion in Biotechnology</i> , <b>1999</b> , 10, 454-7	11.4	54
11	Modifying the host range properties of retroviral vectors. <i>Journal of Gene Medicine</i> , <b>1999</b> , 1, 300-11	3.5	78
10	Modification of retroviral tropism by display of IGF-I. <i>Journal of Molecular Biology</i> , <b>1999</b> , 285, 485-94	6.5	41
9	In vivo selection of protease cleavage sites from retrovirus display libraries. <i>Nature Biotechnology</i> , <b>1998</b> , 16, 951-4	44.5	63
8	Inverse Targeting of Retroviral Vectors: Selective Gene Transfer in a Mixed Population of Hematopoietic and Nonhematopoietic Cells. <i>Blood</i> , <b>1998</b> , 91, 1802-1809	2.2	63
7	A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. <i>Journal of Virology</i> , <b>1998</b> , 72, 9955-65	6.6	93
6	Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. <i>Journal of Virology</i> , <b>1998</b> , 72, 5313-7	6.6	39
5	A gene delivery system activatable by disease-associated matrix metalloproteinases. <i>Human Gene Therapy</i> , <b>1997</b> , 8, 729-38	4.8	86
4	Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. <i>Virology</i> , <b>1997</b> , 234, 51-61	3.6	38
3	Retroviral vectors displaying functional antibody fragments. <i>Nucleic Acids Research</i> , <b>1993</b> , 21, 1081-5	20.1	192
2	Serotypic Evolution of Measles Is Constrained by Multiple Codominant B-Cell Epitopes on Its Surface Glycoproteins. <i>SSRN Electronic Journal</i> ,	1	1
1	Pathogenic measles viruses cannot evolve to bypass vaccine-induced neutralizing antibodies		4